Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Any week bro we received email it’s happening
Yes good luck to everyone with shares here , I believe this will be rewarding to the ones who need treatments and the shareholders for believing in the company. GLTA
I think the few of us put together in this forum combined is atleast carrying 7-10 percent of the 983m o/s float
I'm sitting with 8.5 million shares between my regular account and my Roth IRA! I only wish I could have 15 million shares!
That is an awesome position and if this works out the way I believe it will you will be sitting very well on those shares.
What a pleasant surprise to see my RSPI in the green! This is just a taste to what's to come once they bring this back to current status!
Yes the increase is on one of my accounts that holds 11,640,000 share so this increase shot it up. My avg is.00114 , just wish I was able to buy when it went into EM but I am fine with the 15m I currently have . GLTA
Symbol Change $ Change % Qty # Price Paid $ Day's Gain $ Total Gain $ Total Gain % Value $
RSPI 0.0013 108.33% 11,640,000 0.00114 15,132.00 15,759.70 118.14% 29,100.00
I wish I had that money damn it!
Yes the increase is on one of my accounts that holds 11,640,000 share so this increase shot it up. My avg is.00114 , just which I was able to buy when it went into EM but I am fine with the 15m I currently have . GLTA
Yeah definitely only the starting point if human trials go as planned fda approval should be on horizon.
Also agree with u as we know their Australia subsidiary being labeled at 25m valuation u have to imagine minimally with all their compounds and assets put together we should reach a point of 100m valuation with any real word success for their products.
I’m unfamiliar how long are human trials conducted till we get word on the results?
Not sure if this has been posted , but a nice read and values for another way to invest GLTA
https://www.primarymarkets.com/capital-raising-company/resolutionrx/
The upcoming phase 2 DOD SCI trial should have many eyes on it as my opinion is it can really launch the ampakine program into the limelight and parlay into many other trials, ADHD being a big one. Then the gabakine KRM-ll-81 has shown preclinical superiority and NIH tier 3 must have went well to enable hiring a premier consulting firm to handle grants likely forthcoming.
Important company making activities are in motion.
Considering how they value the OSA program...
3 pennies is less than 30 million market valuation! In my opinion the amapkine program is worth more than the OSA program and the gabakine program may end up being the King of them all.
Would love to see this stair step up over the next 3-6 months building a stronger and stronger base where the 3 platforms can launch from and exploit the potential into many human clinical trials.
In the expert market if someone wants to buy this they know what they are doing, I guess, by definition. They really mean to acquire this. Like an auction at Christie’s. So the share price can take off in there, for most onlookers to just watch and drool. Hello everyone!! I get to keep my saliva in my head.
Thanks for update , nice 15k gain today GLTA
Once they file all the missing documents/reports, they will be taken off EM.
We all agree with that just looking towards the positives how sp is recovering. Agree tho unless they are shifting around assets or a clear need for EM no excuse for us to be here
Bro u were asking me a few weeks ago how laughing at the situation. U see now look how we are trading and we aren’t even in u.s markets yet. No matter the industry or economy condition the market will always comply to product value. And here we are still incredibly undervalued.
Fuck that when we get current we going straight to 3 cents if this is how we are trading
Bro I’m so happy just seen it
Sure thing, he went radio silent for a bit but responded this time!
TY for your Contacting RSPI
November 18-20, 2024 | Boston, MA Arnold Lippa Company: RespireRx Pharmaceuticals Inc
Company: RespireRx Pharmaceuticals Inc
Job title: CEO and CSO
Seminars:
Re-Purposing Dronabinol Using Proprietary Formulations for New Therapeutic Indications, Specifically Obstructive Sleep Apnea (OSA) 9:30 am
Looking at Dronabinol’s potential to stabilize respiratory patterns and augment upper airway muscles Introducing drug formulation innovation in the form of proprietary lipid nanoparticle technology to enhance solubility and absorption Enhancing Dronabinol stability and ease of manufacturing to support commercial scaleRead more
day: Conference Day 1
Re-Purposing Dronabinol Using Proprietary Formulations for New Therapeutic Indications, Specifically Obstructive Sleep Apnea (OSA) 9:30 am
Looking at Dronabinol’s potential to stabilize respiratory patterns and augment upper airway muscles Introducing drug formulation innovation in the form of proprietary lipid nanoparticle technology to enhance solubility and absorption Enhancing Dronabinol stability and ease of manufacturing to support commercial scaleRead more
day: Day One AM
https://cannabinoid-derived-drug-development.com/speakers/
https://cannabinoid-derived-drug-development.com/speakers/
November 18-20, 2024 | Boston, MA
Disagree. EM is 💯 where it should be right now. They have an obligation to keep financial records current. End of story
Can’t wait to see this trade pennies.
Somebody posted it quite awhile ago now, it was sometime in November I believe.
Oh boy with PPS back in a range like before EM, seems like EM not having so much impact on our PPS. Should have never been on EM but I’m confident mgmt has a plan for us!
When is that expo RSPI is attending? November?
Green always makes one feel happy....
However, it is still only maybe $1500 or so in dollar volume. Going to continue to be just crumbs floating around until this gets current and we start to get updates flowing.. Fingers crossed sooner than later on that. Regardless... GREEN is GOOD...
Great day, things looking up!
Wow... what's going on? 🤠
$RSPI
Nice buy at .0025 today !
This is something I think most would agree with.
First impressions and professional appearance important JMHO
Considering the huge number of neurologically active molecules that RSPI controls, it should be mind blowing for the biotech investors who haven't been following the neurological literature.
We can only hope there is some reasonable timeline to almost reintroduce the company and the drug platforms to the investment community. To me, no better time than right before the phase 2 government funded clinical trial kicks off. I think investors would like to hear alot more about this trial and what they are hoping to achieve and how this parlays into other medical indications such as ADHD and others. Which compounds more suitable CX-1739 or CX-717 or another?
Also the tier 3 NIH preclinicals. How successful was those efforts considering they have hired consultants to take the next step and move the gabakine into human trials.
Start improving communications and building out your investment base so as 2025 begins to unfold and grant funding comes in and they do parlay the ampakine program into more trials they build from a bigger base of investors, sustaining the companies endeavors. Oh and whatever is happening with the OSA program too!
This pipeline has been extremely undervalued for years, they have continued to acknowledge that in the filings for years. Time for that to change... I hope.
That is good to hear that they acknowledged a deficiency.
The website clarity and accurate up-to-date information is a critical component to raising awareness for investors as well as potential partners and collaborators. All part of telling your company's story in my opinion.
Thank god. Hopefully by the end of October by the latest
Yes He was silent up to EM maybe they more optimistic now!
Maybe the next time we hear from him is congratulating us shareholders and introducing us to the Eli Lilly CEO 👀🤣💰
Followers
|
346
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
51570
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators DTGoody crazy horse 0 Lime Time archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
Form Type | Received | Period End Date | Report |
---|---|---|---|
8-K | 07/08/2024 | 07/02/2024 | PDFRTFHTMLXLS |
8-K | 05/29/2024 | 05/29/2024 | PDFRTFHTMLXLS |
8-K | 04/16/2024 | 04/10/2024 | PDFRTFHTMLXLS |
NT 10-K | 04/01/2024 | 12/31/2023 | PDFRTFHTMLXLS |
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |